Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 25Recruiting 17Completed 3Suspended 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Castration-resistant Prostate Cancer 1

Interventions

Specimen Handling 22Magnetic Resonance Spectroscopy 20Carboplatin 17Gemcitabine 15pembrolizumab 13Cisplatin 13Paclitaxel 12Injections 11Interviews as Topic 10fludarabine 9Radiotherapy 9Cyclophosphamide 9Oxaliplatin 8Dexamethasone 8Biopsy 8Bevacizumab 8toripalimab 7Nivolumab 7Irinotecan 7Fluorouracil 7Bortezomib 7X-Rays 6Radiosurgery 6Pemetrexed 6Leucovorin 6Capecitabine 6durvalumab 5cemiplimab 5anlotinib 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × olaparib × 30 days × Clear all
NCT07641855 2026-06-11

A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
180 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡